

• APPLICANTS: Comb *et al.*
U.S.S.N.: 10/014,485

REMARKS

Claims 1, 17-20, 22, and 27-45 have been withdrawn (corresponding to Groups I, III-VI, and IX-XV). Claims 5-10 within Group II have been voluntarily cancelled. Upon entry of the present amendment, claims 2-4, 11-16, 21, and 23-26 are presently pending. The pending claims correspond to subject matter of remaining Groups II, VII and VIII.

Applicants have voluntarily amended certain of the claims to more clearly define the features and characteristics of the claimed subject matter. Claims 2, 15, and 16 have been amended to recite proper dependency. Claims 11-13 and 23-25 have been amended to more accurately recite "protein-protein" binding motif rather than "protein" binding motif and to eliminate certain typographical errors. Claim 4 has been amended to recite an additional preferred species previously recited in withdrawn claim 8. Independent claim 3, drawn to a method of producing a preferred genus of antibodies of the invention, has been voluntarily amended to more clearly define that the antibody "specifically binds a recurring, modified motif" in a plurality of peptides or proteins within "an organism in which it recurs." Claim 3 has also further been amended to recite that the motif for which the antibody is specific comprises "two" to six invariant amino acids, and may further include "optionally, one or more degenerate amino acid positions(s)." Independent claim 21 has also been voluntarily amended to recite the same changes made to claim 3, and further to recite that the target motif includes at least one "phosphorylated" amino acid.


These amendments are supported throughout the specification, including the claims, as originally filed, and do not introduce new matter. The present amendments place the present claims in better form for expeditious prosecution and allowance in the present case.

APPLICANTS: Comb *et al.*
U.S.S.N.: 10/014,485

Conclusion

The present claims are believed to be in condition for immediate allowance. Reconsideration and withdrawal of the remaining restriction requirement pertaining to the pending claims is respectfully requested. Early and favorable consideration and allowance of these claims is earnestly solicited. If there are any questions regarding these remarks, the Examiner is requested to call the undersigned attorney at the telephone number provided.

Respectfully submitted,



James Gregory Cullem, J.D., Reg. No. 43,569
Intellectual Property Counsel
CELL SIGNALING TECHNOLOGY, INC.
166B Cummings Center
Beverly, MA 01969
(978) 867-2311

Date: March 16, 2004